#HEMOSTATIC GELATIN SPONGE

[aegislifescience]

Revolutionizing Surgical Hemostasis: Introducing Surgi-ORC® Powder (Absorbable Hemostatic Powder)

In modern surgery, efficiently managing perioperative bleeding is crucial. Uncontrolled surgical bleeding poses significant risks to patient health and leads to substantial clinical and healthcare resource burdens. This challenge is particularly pronounced with an aging population and the rising prevalence of comorbidities and anticoagulant use. To address these issues, topical hemostatic agents have emerged as vital tools, promoting hemostasis where conventional methods fall short. These agents vary widely in properties, mode of action, ease of use, safety, and cost. Their selection often depends on the specific surgical scenario, bleeding situation, and patient’s health status.

Exploring Topical Hemostatic Agents

The current array of topical hemostatic agents comprises several types, each designed to meet different needs in the surgical setting:

Mechanical Agents: These are regarded as the simplest, safest, and most cost-effective. They offer a structural framework for hemostasis and are particularly useful in providing immediate bleeding control.

Active Agents: These utilize human, bovine, or recombinant thrombin. They actively engage the clotting process, making them effective in more challenging bleeding scenarios where mechanical agents might not suffice.

Gelatin-Thrombin Matrix Agents (Flowables): These combine gelatin and thrombin to provide a more adaptable solution that can conform to irregular wound surfaces, enhancing the hemostatic effect.

Sealants: Made from human fibrinogen or (semi)synthetic compounds, sealants form a fibrin clot that helps stop bleeding and can also promote tissue healing.

Among these, absorbable hemostatic powders stand out as revolutionary products designed to optimize surgical outcomes. Powdered hemostats are especially advantageous for their ease of use and efficacy in controlling continuous oozing bleeding of mild to moderate intensity over large surfaces [1, 2]. Their versatility and effectiveness make them an essential component in the surgical toolkit.

The Game-Changer: Surgi-ORC® Powder

Aegis Lifesciences is pleased to introduce Surgi-ORC® powder, an absorbable hemostat made from natural, plant-based oxidized regenerated cellulose, providing an effective solution for bleeding control.Surgi-ORC® Powder, in particular, is a natural, plant-based absorbable hemostat made from oxidized regenerated cellulose. It is specifically designed for faster control of continuous bleeding across broad surfaces and is suitable for both open and laparoscopic procedures.

Imagine a powder prefilled in a bellow bottle/applicator, ready to dispense directly onto a target bleeding site. Surgi-ORC® Powder is white with a pale yellow color and has a faint, caramel-like aroma. It effectively controls capillary, venous, and smallarterial haemorrhage and is fully absorbable. Surgi-ORC® Powder achieves hemostasis faster than other variants of Surgi-ORC® products.

Why Choose Surgi-ORC® Powder?

Composition and safety: Made from oxidized regenerated cellulose, Surgi-ORC® Powder ensures biocompatibility and safety. Being a natural, plant-based absorbable haemostat, it contains no animal-origin or collagen additives, making it suitable for patients with allergies or sensitivities.

Ease of application: Versatility is key. Surgi-ORC® Powder can be applied dry, directly onto bleeding areas or organs, making it suitable for various surgical procedures.

Rapid haemostasis: Time is of the essence in surgery. Surgi-ORC® Powder stops bleeding within minutes, which is crucial for complex surgeries to prevent complications.

Absorbable and biocompatible: Fully absorbable with minimal tissue reaction, Surgi-ORC® Powder reduces the risk of post-operative complications.

Antibacterial properties: The low pH of Surgi-ORC® Powder provides an antibacterial effect, reducing the risk of post-operative infections.

Convenience: Stored at room temperature and ready-to-use without any preparation, Surgi-ORC® Powder enhances surgical efficiency.

Durability in hemostasis: Surgi-ORC® Powder is designed to maintain hemostasis even under irrigation, ensuring stability during surgical procedures.

Mechanism of action

When Surgi-ORC® Powder comes into contact with blood, it forms a brownish or black gelatinous mass. This mass acts as a physical matrix to which platelets can adhere. As platelet aggregation occurs and a platelet-fibrin plug forms, the swelling material generates pressure on the surrounding tissue, contributing to haemostasis. Excess haemostat can be removed by irrigation with sterile water or saline solution after bleeding has stopped without disturbing the clot.

Surgi-ORC® powder Usage area

Simple, Fast, and Safe Application

Applying Surgi-ORC® Powder is straightforward. Due to its structure and penetrating ability, it may not require manual compression, making it optimal for minimally invasive procedures or open surgeries where manual compression is difficult to achieve.

Conclusion

Surgi-ORC® Powder represents a paradigm shift in surgical hemostasis, offering surgeons a reliable and efficient solution to manage perioperative bleeding. With its exceptional performance, user-friendly attributes, and demonstrated efficacy, Surgi-ORC® Powder is set to redefine standards in perioperative bleeding management, ensuring safer and more efficient surgical outcomes for patients worldwide.

[healthcare-domain]

Key Players, SWOT Analysis, Key Indicators, Forecast and COVID 19 Impact Analysis For Hemostats Market

By type, the Hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. The thrombin-based hemostats segment accounted for the largest share in the hemostats market in 2020. The large share of this segment can primarily be attributed to the advantages associated with the use of thrombin-based hemostat.

Currently, the lack of skilled surgeons, both in developed and developing economies, is one of the major factors limiting the adoption of these products. For instance, the Association of American Medical Colleges (AAMC) projects a shortage of about 122,000 physicians by 2032 in the US. Of these, a shortage of 12,000 medical specialists and 23,400 surgeons and 39,100 other specialists such as neurologists and radiologists is expected to occur by 2032.

The technology landscape and application areas of hemostats products are changing rapidly, owing to technological advancements in this field. This necessitates physicians and other healthcare providers to acquire the necessary skills to apply advanced hemostats products such as hemostats, bone graft substitutes, surgical sealants, and adhesives effectively. Therefore, surgeons and physicians in hospitals and clinics are reluctant to use advanced surgical products for wound closure.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619

Based on formulation, the hemostats market is segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2020, the matrix & gel hemostats segment accounted for the largest share of the hemostats market. The large share of this segment can be attributed to the advantages associated with these hemostats, such as easy application, biocompatibility, and cost-effectiveness.

With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. the number of surgical procedures declined precipitously, with countries worldwide being affected by the pandemic.

Some of the major players operating in this market are  C.R. Bard (US), Baxter (US), Teleflex Incorporated (US), Ethicon (Subsidiary of Johnson & Johnson) ( US), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany),  Pfizer (US), etc. In 2020, Ethicon (Subsidiary of Johnson & Johnson) ( US) held the leading position in the market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the Hemostats market is its key strength. Baxter (US) held the second position in the market in 2020.

[expert-market-research]

Global Hemostats Market To Be Driven By Rising Trend Of Incidence Of Several Types Of Chronic Diseases And Surge In Surgical Procedures In The Forecast Period Of 2021-2026

The new report by Expert Market Research titled, ‘Global Hemostats Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global hemostats market, assessing the market based on its segments like by product, formulation, indication, application, end use and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.

Request a free sample copy in PDF or view report summary : https://www.expertmarketresearch.com/reports/hemostats-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

Historical Market Size (2020): USD 3.8 Billion

Forecast CAGR (2021-2026): 4%

Forecast Market Size (2026): USD 5.2 Billion

The most important driver of the world market has been an increase in the number of operations performed worldwide, which has given a major boost to the increasing occurrence of bleeding complications during the procedure, leading to market growth of hemostats. But due to the high cost of the product, the growth could be impeded.

Industry Definition and Major Segments

A hemostat is a medical instrument used to control bleeding during certain surgical procedures. Hemostats are part of a class of instruments that pivot (similar to scissors and including needle holders, tissue holders, and various clamps) and the role is determined by the shape of the blade. In emergency wound treatment, hemostats serve three purposes. Hemostats were originally intended to clamp narrow blood vessels in order to control haemorrhage. Another use is for grasping and securing superficial fascia when weakening and debriding wounds. Finally, this instrument is ideal for revealing, discovering, and visualising deeper regions of a wound.

Read Full Report Online : https://www.expertmarketresearch.com/reports/hemostats-market

By product, the market is divided into:

Combination

Thrombin-Based

Gelatin-Based

Collagen-Based

Oxidised Regenerated Cellulose Based

Others

Based on formulation, the market is categorised into:

Sheet and Pad

Sponge

Matrix and Gel

Powder

Others

On the basis of indication, the market is divided into:

Surgery

Wound Closure

Others

Based on application, the market is segmented into:

Cardiovascular Surgery

General Surgery

Gynaecological Surgery

Orthopaedic Surgery

Reconstructive Surgery

Neurological Surgery

Others

By end use, the market is categorised into:

Clinics

Hospitals

Ambulatory Centres

Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Market Trends

The increasing number of operations, the numbers of regulatory approvals, the increase in sports-related injuries and spinal disorders, and an increasing emphasis on successful management of blood loss in patients in surgical procedures, drive growth in this industry. Moreover, the emerging markets and growth in the number of hospitals and surgical centres are expected to give players operating in the Hemostat sector additional opportunities for growth over the forecast period.

The hemostats demand in North America is projected to be the largest in the world. In North America, the hemostats industry is well-established, with the United States serving as a primary market. In the forecast timeframe, China and India are projected to provide major growth opportunities for market players, owing to improved healthcare facilities, rising medical tourism, and an increase in the number of elderly people in the country.

Key Market Players

The major players in the market are Teleflex Incorporated., B. Braun Melsungen AG, Integra LifeSciences Corporation, Pfizer Inc., Baxter International, Inc. , Johnson & Johnson Services, Inc., among Others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact

Company Name: Claight Corporation

Contact Person:-Adam Lee, Business Consultant

Email: sales@expertmarketresearch.com

Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790

Address: 30 North Gould Street, Sheridan, WY 82801, USA

City: Sheridan

State: Wyoming

Country: United States

Website: www.expertmarketresearch.com

[marketinsightshare]

Hemostasis Products Market to Grow at a CAGR of 4.6% During the Forecast Period 2021-2026

"Increasing Prevalence of Chronic Diseases Such as Cardiovascular Diseases, Cancer, Myocardial Infarction Coupled With the Rising Incidence of Trauma and Accidents Across the Globe Are the Major Factors Driving the Growth of the Market."

Hemostasis Products Market size in 2020 is estimated to be $1.52 billion, growing at a CAGR of 4.6% during the forecast period 2021-2026. Hemostasis is the act of stopping blood flow from a damaged vessel or organ. Hemostasis products are the tools that help to control bleeding during surgery and also acts as Fresh Frozen Plasma. Hemostasis products help in fewer blood transfusions, decreased operating time, and reduced morbidity and mortality for patients. It contains Polysaccharides, Oxidized Regenerated Cellulose, which is a hemostatic agent used for hemostasis in surgery and eliminates the risk of viral transmission and increases patient safety. These products are very effective in cases of inhibited coagulation, independent of clotting ability. The increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, Myocardial Infarction coupled with the rising incidence of trauma and accidents across the globe are the major factors driving the growth of the market. Moreover, growing technological advancement in hemostasis products coupled with rising usage of recombinant products further enhance the overall demand for the Hemostasis Products Market during the aforesaid period.

Hemostasis Products Market Segment Analysis - By Product Type

Based on the Technology, Hemostasis Products Market is segmented into Topical Hemostasis Product, Infusible Hemostasis Product, Advanced Hemostasis Product. The topical hemostasis product segment is estimated to dominate the market during the period 2021-2026. This is attributed to rising usage of topical hemostasis products during surgery, trauma to maintain hemostasis. Topical hemostasis products include polysaccharides, collagen, gelatin, and others. The advanced hemostasis products segment is forecast to be the fastest-growing segment and is projected to grow at a CAGR of 4.0% during the period 2021-2026. This is mainly owing due to the increased usage and product trust in surgical suites and it provides faster and more sustained hemostasis.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=16948

Report Price: $ 4500 (Single User License)

Hemostasis Products Market Segment Analysis - By Application

Based on the application, Hemostasis Products Market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke, and Thrombosis. In 2020, surgery is estimated to hold a major share in the market. This is mainly owing to the rising number of surgical procedures across the globe. Moreover, hemostasis products that contain thrombin which is safe and effective than alternative to gelatin sponges and oxidized cellulose in controlling bleeding during cardiac surgery are also contributing to the dominance of this segment. Also, trauma is projected to grow with a CAGR of 3.7% over the period 2021-2026. This is owing to the rising number of traumatic incidents including accidents.

Hemostasis Products Market Segment Analysis - By Geography

North America dominated the Hemostasis Products market share accounting for 40% of the market in 2020. This is mainly owing to the rising incidence of road accidents in countries such as the U.S. and Canada. According to, a report published by the U.S. Department of Transportation, National Highway Traffic Safety Administration, in 2018, there were 36,560 people killed in motor vehicle traffic crashes on U.S. roadways. However, the Europe region is projected to be the fastest-growing over the period 2021-2026. This is owing to rising expenditure on healthcare which leads to demand technologically advanced products owing to strong surgeries volume.

Hemostasis Products Market Drivers

Increasing Prevalence of Chronic Diseases

Increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, Myocardial Infarction coupled is driving the growth of Hemostasis Products market. According to, National Centres for Disease Control and Prevention (CDC), chronic diseases such as cancer, diabetes, Myocardial Infarction are the leading cause of death in U.S. which accounts for nation’s $3.8 trillion in annual health care costs. Moreover, rising number of surgeries in outpatient settings owing rising geriatric population is also set to increase the market growth.

Rising Technological Advancement

Increase in research and development in products with a technologically advanced features is also driving the market. The advancement in R & D of the products reduces the risk of infection and transmission. For instance, TISSEEL the product offering by Baxter which is the most technologically advanced product contains fibrin sealant for surgical care. Also, the increasing adoption of recombinant products is also set to the growth of the Hemostasis Products Market.

Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=16948

Hemostasis Products Market Challenges

High capital expenditure required for these products owing to the usage of advanced technology for hemostat is challenging the market. Along with this the certain clinical limitation, which in some cases such as uncontrolled bleeding that leads to the limited adoption of these products are also further challenging the growth of the market.

Covid-19 Impact

Moreover, the outbreak of COVID-19 around the world has impacted all industries including the healthcare industry. Covid-19 affects the Hemostasis Products market including a drastic reduction in emergency surgical procedures and also overall admission to the Emergency department (ED). Also owing to the widespread of coronavirus, it affects non-essential medical procedures such as plastic surgery and others that are not linked to the treatment of COVID-19. These affect the Hemostasis Products market by the cancellation of scheduled surgery and shift of surgeons to the other area.

Hemostasis Products Market Industry Outlook

Product launches, Merger & Acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Hemostasis Products Market. Hemostasis Products top 10 companies are Baxter International, Inc., Medtronic, Johnson & Johnson, Pfizer, Inc., Cryolife, Inc., Stryker, Tricol Biomedical, Dexur, C. R. Bard, Inc., and Grifols, S.A.

Acquisitions/Product Launches:

In February 2020, Terumo launched AQUABRID, a new surgical sealant in the EMEA market. These product is optimized to stop bleeding during surgical procedure.

In June 2019, Baxter International, Inc. launched its new hemostasis product, Floseal Hemostatic Matrix. This product is approved by USFDA and helps to stop bleeding during the procedure.

Key Takeaways

In 2020, North America dominated the Hemostasis Products Market owing to the rising number of road accidents in the region.

Increasing development in healthcare infrastructure across the globe is driving the market growth of Hemostasis Products.

Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the Hemostasis Products Market report.

The High cost of the products and some certain clinical limitation are challenging the growth of the market.

Related Reports :

A. Hemostasis And Tissue Sealing Agents Market

https://www.industryarc.com/Research/Hemostasis-And-Tissue-Sealing-Agents-Market-Research-503679

B. Coagulation/Hemostasis Analyzer Market

https://www.industryarc.com/Report/16786/coagulationhemostasis-analyzer-market.html

For more Lifesciences and Healthcare Market reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

[marketresearchstrategy]

Hemostat  Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2026

The global hemostat market is a fast-growing sector and is widely driven by the increasing number of surgeries acquainted with chronic disorders and the rise in the number of sports accidents among athletes and gymnasts.

the hemostats market was valued at USD 2.11 billion in 2018 and is expected to reach USD 3.46 billion by the year 2026, at a CAGR of 6.2%. It is a surgical instrument that is used to control the flow of blood during surgical procedures. These surgical hemostats are used in the initial steps of surgery when an incision is performed. It can be used in various forms like sealants, topical hemostats, and mechanical instruments, which are meant for surgical use only. The major goal of a hemostat is the adhesion of wounds, to cease blood flow, and ensure rapid healing of the wound. The hemostat market is widely driven by the free fall in lifestyle due to which lifestyle-oriented diseases occur in many people. Various diseases, especially cardiovascular and orthopedic diseases, are treated through surgical procedures, which is extensively driving the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2516

The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.

Key Manufacturers in the Global Hemostat  Market:

Johnson and Johnson, Baxter International, Pfizer, Integra Life Sciences, Z-Medica LLC, Abbott Laboratories, B. Braun Melsungen AG, CR Bard, Gelita Medical GmbH and Hemostasis LLC.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2516

The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of Europe)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Product Outlook (Revenue in Million USD; 2016–2026)

Thrombin-based hemostats

Gelatin-based hemostats

Collagen-based hemostats

Combination hemostats

Oxidized regenerated cellulose-based hemostats

Application Outlook (Revenue in Million USD; 2016–2026)

General surgery

Orthopedic surgery

Cardiovascular surgery

Reconstructive surgery

Gynecological surgery

Neurological surgery

Other surgeries

Formulation Outlook (Revenue in Million USD; 2016–2026)

Sheet & pad hemostat

Sponge hemostats

Matrix & gel hemostats

Powder hemostat

End Use Outlook (Revenue in Million USD; 2016–2026)

Hospitals

Clinics

Ambulatory centers

Community healthcare

Others

To know more about the report @ https://www.reportsanddata.com/report-detail/hemostat-market

Key Questions Addressed in the Report:

What is the market size the global Hemostat  market is expected to reach over the forecast period? What is the expected CAGR?

What are the key segments of the market?

What are the key products and applications of the Hemostat  market?

What factors are expected to drive and restrain market growth over the forecast period?

What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2516

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.

Browse more Details:

Neuroscience Antibodies and Assays Market:      https://www.biospace.com/article/neuroscience-antibodies-and-assays-market-size-to-reach-usd-7-06-billion-in-2028-says-reports-and-data-/

Cochlear Implant Market:             https://www.biospace.com/article/cochlear-implant-ci-market-size-to-reach-usd-4-21-billion-in-2028-noted-reports-and-data-/

Creatinine Measurement Market:            https://www.biospace.com/article/creatinine-measurement-market-size-to-value-at-usd-841-01-million-in-2028/

Lung In Vitro Model Market:       https://www.biospace.com/article/lung-in-vitro-market-size-to-reach-usd-976-9-million-in-2028-says-reports-and-data/

C-Reactive Protein Testing Market:          https://www.biospace.com/article/c-reactive-protein-testing-market-size-to-reach-usd-1-93-billion-in-2028-says-reports-and-data-/

Read Full Press Release: https://www.reportsanddata.com/press-release/global-hemostat-market

[ojasdbmr]

Hemostat can be defined as a surgical tool that is used to control blood loss or halt bleeding during major surgical. Basically it is used in early phases of surgery for an initial incision that closes blood vessels until ligation. It contain group of instruments which include needle holders, pivot, various clamps and various clamps.

[sandlerresearch]

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2026 published on

https://www.sandlerresearch.org/hemostats-market-by-type-thrombin-oxidised-regenerated-cellulose-combination-gelatin-collagen-application-orthopedic-surgery-general-surgery-gynecological-formulation-sponge-powder-matr.html

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2026

“The Hemostats market is projected to grow at CAGR of 6.1% from 2021 to 2026”

The global Hemostats market size is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.1% during the forecast period. Growth in this market is driven by the growing volume of surgical procedures performed, rising focus on R&D, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries. However, side effects and allergic reactions associated with hemostats are expected to hamper the adoption of these products. Moreover, the growth opportunities in emerging markets are expected to provide growth opportunities for players in the Hemostasts market during the forecast period.

“Thrombin-based hemostats segment to witness the highest growth during the forecast period.”

Based on the type, the Hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. The thrombin-based hemostats segment accounted for the largest share in the hemostats market in 2020. The large share of this segment can primarily be attributed to the advantages associated with the use of thrombin-based hemostat

“Matrix & gel hemostats segment to register the highest growth in the Hemostats market during the forecast period.”

Based on formulation, the hemostats market is segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2020, the matrix & gel hemostats segment accounted for the largest share of the hemostats market. The large share of this segment can be attributed to the advantages associated with these hemostats, such as easy application, biocompatibility, and cost-effectiveness. On the other hand, the sponge hemostats segment is expected to witness the highest growth in the market during the forecast period due to the growing acceptance of these formulations by end users.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the Hemostasts market five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The high growth in this market is attributed to the increasing prevalence of chronic diseases, increasing per capita income leading to improving standard of living, increasing healthcare spending, growing demand for better quality medical care, and the rising awareness about hemostats in several APAC countries.

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (55%), Tier 2(25%), and Tier 3 (20%)

By Designation: C-level (43%), Director-level (32%), and Others (25%)

By Region: North America (38%), Europe (23%), AsiaPacific(29%),Latin America (7%),  and Rest of the WorlMiddle East & Africa (3%)

List of Companies Profiled in the Report:

C.R. Bard (US)

Baxter (US)

Teleflex Incorporated (US)

B. Braun Melsungen AG (Germany)

Ethicon (Subsidiary of Johnson & Johnson) ( US)

Medtronic plc (Ireland)

Hemostasis, LLC (US)

Pfizer (US)

stryker corporation (U.S.)

CryoLife (US)

Marine Polymer Technologies (US)

Gelita Medical GmbH (Germany)

Advanced Medical Solutions Group (U.K.)

Betatech Medical (Turkey)

Meril Life Sciences Pvt Ltd (India)

Samyang Holdings Corporation (South Korea)

BIOM’UP (France)

BiocerEntwicklungs-GmbH (Germany)

Unilene (US)

Integra life sciences (US)

Katsan Medical Devices (Turkey)

Tricol Biomedical Inc. (US)

Stersil Hemostat (Germany)

3-D Matrix ltd. (Japan)

Medtrade Products Limited (UK)

Altaylar Medical  (Turkey)

Research Coverage

This report studies the Hemostasts market based on product, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Hemostasts market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on Hemostasts products offered by the top 26 players in the Hemostasts market. The report analyzes the Hemostats market by type, formulation, Application and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various secure Hemostasts across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Hemostasts market.

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Hemostasts market

[kunalcmi]

EUROPE GELATIN AND BONE GLUE MARKET ANALYSIS (2020-2027)

Gelatin is a protein substance derived from collagen, a structural protein present in the ligaments, tendons, and tissues of mammals. It is extracted from the bones, hides, and skin of the mammals. Gelatin is used to form strong and transparent gels and flexible films. It is used in the form of bone void fillers, hemostatic sponges, and biodegradable orthopedic implants.

Statistics:

Europe gelatin and bone glue market is estimated to account for US$ 310.4 Mn in terms of value by the end of 2027.

Europe Gelatin and Bone Glue Market: Drivers

Increasing prevalence of bone related disorders is expected to propel growth of Europe gelatin and bone glue market over the forecast period. For instance, according to GlobalData Plc, there will be over 171 million total prevalent cases of osteopenia in the US, France, Germany, Italy, Spain, the U.K., and Japan in 2018 compared to over 162 million total prevalent cases in 2017.

Increasing adoption of gelatin and bone glue in sports injuries is also expected to aid in growth of the market. Gelatin based hemostat and bone glue can be effectively used in sports injuries such as fractures and whiplash injuries to control bleeding effectively and reunite the fractured bone without the use of plates and screws.

Statistics:

Germany held dominant position in Europe gelatin and bone glue market in 2019, accounting for 23.5% share in terms of volume, followed by France and U.K., respectively

Figure 1: Global Gelatin and Bone Glue Market Share (%) in Terms of Value, By Country, 2019

Europe Gelatin and Bone Glue Market: Restraints

Complications related to cemented arthroplasty are expected to hinder growth of the market. Significant risks and complications are associated with cemented arthroplasty procedures such as inflammation of surrounding soft tissues and breakdown of cement, which may prompt the need for second arthroplasty surgery. Moreover, cemented joint arthroplasty may lead to bone cement implantation syndrome (BCIS), which may decrease adoption of the procedure.

Moreover, high cost of gelatin and bone glue products is expected to hamper growth of the market

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/3793

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/3793

Europe Gelatin and Bone Glue Market: Opportunities

Increasing cases of sports-related injuries is expected to offer lucrative growth opportunities for players in market. For instance, according to the study, “Results on sports-related injuries in children from NHS emergency care dataset Oxfordshire pilot: an ecological study”, published in the Journal of the Royal Society of Medicine, in October 2018, children and adolescents aged 0–19 years in a study in U.K. accounted for 47.4% of sports injury-related emergency department attendances and 23.5% of sports injury-related admissions for all ages.

The bone environment is subject to specific and challenging requirements in terms of biocompatibility, degradability, and bond strength. Major players can therefore, focus on developing bone adhesives that combine these three important requirements.

Statistics:

Figure 2: Global Gelatin and Bone Glue Market Value (US$ Mn), 2016 - 2027

Europe gelatin and bone glue market was valued at US$ 193.0 Mn in 2019 and is forecast to reach a value of US$ 310.4 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027.

Market Trends/Key Takeaways

Increasing prevalence of diabetes is expected to lead to high number of amputations, thereby aiding in growth of the market. For instance, according to Diabetes UK, over five million people will suffer from diabetes in the U.K. by 2025.

Moreover, increasing number of amputations is expected to aid in growth of Europe gelatin and bone glue market. For instance, according to Public Health England, the U.K. recorded 27,465 amputations between 2015 and 2018, compared with 24,181 cases between 2012 and 2015.

Regulations:

Medical devices manufacturers are free to approach any NB in Europe that has been designated for the respective conformity assessment procedure

NB: The lists of notified bodies are given ‘for information only’ and are valid till the date indicated. Information is made available as provided by the designating authorities of the member states. 

Europe Gelatin and Bone Glue Market: Competitive Landscape

Major players operating in include, Johnson & Johnson, Baxter International Inc., CryoLife, Inc., Becton, Dickinson and Company, Luna Innovations Incorporated, B. Braun Melsungen AG, Cohera Medical, Inc., Integra LifeSciences Corporation, Tissuemed Ltd., and Chemence Medical, Inc.

Europe Gelatin and Bone Glue Market: Key Developments 

Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in February 2020, Baxter International Inc. acquired Seprafilm Adhesion Barrier and related assets from Sanofi for US$ 350 million.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/europe-gelatin-and-bone-glue-market-3793

[ajaychandak01]

Hemostat Market with Covid-19 Pandemic Analysis, Growth Rate, New Trend Analysis Forecast To 2027

Industry Overview of the Hemostat Market 2020

The research report titled Global Hemostat Market is an all-inclusive document containing crucial data pertaining to sales and revenue of the Hemostat industry. The evaluations are done on the basis of the analysis of leading market segments such as types, applications, regions, technological advancements, and dominant players of the global Hemostat industry. The report provides historical data (2017-2018) of the industry and provides valuable forecast information for the period of 2020-2027. The report is formulated with the analysis of current and emerging trends based on the impact of the COVID-19 pandemic. The pandemic has changed the dynamics of the market and has drastically shaken up the economic scenario of the world. The report covers an impact analysis of the COVID-19 pandemic and offers a futuristic outlook of a post COVID scenario. It also covers trends, demands, and growth rates impacted by the ongoing crisis.

The forecast estimation states the global Hemostat market is expected to dominate the economic sphere of the world with significant growth in the coming years. The growth is boosted by a change in demand patterns, rapidly developing infrastructure, technological advancements, and product advancements. The current and emerging trends are expected to shape up the industry and help in gaining a strong foothold in the global market to contribute to the revenue generation.

The Global Hemostat market is further analyzed on the basis of key companies operating in the business sphere and major geographical regions where the market has a substantial size and growth rate.

Prominent Players: Johnson and Johnson, Baxter International, Pfizer, Integra Life Sciences, Z-Medica LLC, Abbott Laboratories, B. Braun Melsungen AG, CR Bard, Gelita Medical GmbH and Hemostasis LLC.

Product Outlook (Revenue in Million USD; 2016–2027)

Thrombin-based     hemostats

Gelatin-based     hemostats

Collagen-based     hemostats

Combination hemostats

Oxidized regenerated     cellulose-based hemostats

Application Outlook (Revenue in Million USD; 2016–2027)

General surgery

Orthopedic surgery

Cardiovascular surgery

Reconstructive surgery

Gynecological surgery

Neurological surgery

Other surgeries

Formulation Outlook (Revenue in Million USD; 2016–2027)

Sheet & pad     hemostat

Sponge hemostats

Matrix & gel     hemostats

Powder hemostat

End Use Outlook (Revenue in Million USD; 2016–2027)

Hospitals

Clinics

Ambulatory centers

Community healthcare

Others

  Zonal Partition of the Market: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

The report covers extensive analysis of market segments that are anticipated to lead by the end of the forecast period (2020-2027). The report puts a special emphasis on the upstream raw materials, downstream buyers, industrial chain analysis, technological and product advancements, and production and manufacturing capacities of the Hemostat market. Moreover, the report provides an in-depth analysis of the core segments of the market by analysis of the applications, types, consumption patterns, market drivers and restraints, and challenges to be faced in the market.

The research study focuses on the emerging development patterns and manufacturing processes anticipated to boost the growth of the market. It also includes extensive profiles of prominent contenders of the industry and provides a complete analysis inclusive of their market share, market size, production capacity, sales and distribution network, import/export activity, and product portfolios.

To read more about the report @ https://www.reportsanddata.com/report-detail/hemostat-market

Major objectives of the Global Hemostat Report:

·       Analysis and forecast estimation of the Global Hemostat Market based on the market segmentation into types, applications, and regions

·       Analysis of micro and macroeconomic factors affecting the global Hemostat market

·       Valuable insight into the major drivers, limitations, opportunities, and challenges faced by the global Hemostat market and its players

·       In-depth analysis of the prominent contenders along with their business strategies and expansion plans

·       Strategic recommendations to the established companies as well as new entrants to assist in the formulation of investment plans

·       Comprehensive analysis of the competitive landscape of the Hemostat industry

To summarize, the report provides a better understanding to the reader about the Hemostat industry by offering a detailed explanation of the competitive landscape, industry environment, market projections, growth driving and restraining factors, limitations, entry barriers, and opportunities. The report also covers the regulatory framework, investment opportunities, and other growth driving factors. The report allows the reader to gather insightful information about each segment of the market and provides a historical, present, and prospective outlook of the market.

Thank you for reading our report. To know more about the report or for any queries regarding customization, please connect with us. Our team will provide excellent assistance and make sure the report is tailored to meet your requirements.

Related Reports –

SB Wire  –  http://www.sbwire.com/press-releases/hemostat-market-research-report-covering-prime-factors-and-competitive-outlook-till-2027-johnson-and-johnson-baxter-international-pfizer-1300748.htm

Globe News Wire –  

https://www.globenewswire.com/news-release/2020/03/02/1993769/0/en/Hemostat-Market-to-Reach-USD-3-46-Billion-By-2026-Reports-and-Data.html

[aegislifescience]

SURGISPON® Assisted Surgery for Aneurysmal Bone Cyst in Proximal Tibia

Aneurysmal bone cysts (ABCs) are uncommon bone lesions, and the solid variant (S-ABC) is even rarer, accounting for less than 10% of all ABCs. Despite its rarity, S-ABC presents a significant diagnostic challenge due to its resemblance to neoplastic lesions. In this context, the treatment strategy becomes crucial, and the use of gelatin sponge emerges as a noteworthy adjunct in surgical management.

The Diagnostic Journey

An 11-year-old boy presented with swelling and pain in the right proximal tibia. Despite suspicions of telangiectatic osteosarcoma (TO) based on radiological findings, the final diagnosis was S-ABC. The histopathological features indicated extensive new bone formation, which complicated the diagnostic process but guided the treatment strategy.

Surgical Treatment and the Role of Gelatin Sponge (SURGISPON®)

The patient underwent extended curettage and bone grafting, a procedure where the use of gelatin sponge played a pivotal role. During the surgery, gelatin sponge (SURGISPON®, Aegis Lifesciences) was used to pack the bone graft harvested from the ipsilateral iliac crest and fibular shaft. The sponge serves multiple purposes:

Hemostasis: SURGISPON®promotes hemostasis by absorbing blood and facilitating clot formation, which is crucial in surgeries involving bone curettage where bleeding can be significant.

Bone Graft Stabilization: SURGISPON®provides structural support and stabilization for the bone graft, aiding in its integration and preventing displacement.

Scaffold for Bone Formation: SURGISPON®acts as a scaffold for new bone formation. Over time, the sponge is resorbed, and the bone graft replaces it, promoting healing and bone regeneration.

Fig.1: Surgical Illustration [1]

Postoperative Outcome

Following surgery, the patient had an uneventful recovery. At one-year follow-up, he was asymptomatic, and radiographs showed reformation of the severed fibula, indicating successful bone graft integration with minimal morbidity.

Fig.2: A) Pre-operative X-ray B) Postoperative X-ray showed healed lesion [1]

Conclusion

In conclusion, the case of S-ABC in the right proximal tibia serves as a reminder of the complexities in diagnosing and treating rare bone lesions. The incorporation of gelatin sponge in surgical management demonstrates its value as a versatile tool in orthopedic surgery, contributing to successful outcomes and patient well-being.

[healthcare-domain]

Hemostats Market Size is Projected To Reach USD 3.5 Billion By 2026 at a CAGR of 6.1%

By type, the Hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. The thrombin-based hemostats segment accounted for the largest share in the hemostats market in 2020.

The large share of this segment can primarily be attributed to the advantages associated with the use of thrombin-based hemostat.

Based on formulation, the hemostats market is segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2020, the matrix & gel hemostats segment accounted for the largest share of the hemostats market.

The large share of this segment can be attributed to the advantages associated with these hemostats, such as easy application, biocompatibility, and cost-effectiveness.

[230 Pages Report] The global Hemostats market size is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.1% during the forecast period. Growth in this market is driven by the growing volume of surgical procedures performed, rising focus on R&D, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries.

With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619

The number of hospitals and surgical centers is increasing in both developed and emerging countries. The demand for surgical equipment (including medical devices such as hemostats) is high in these newly established surgical centers and hospitals, owing to the increasing patient population base.  

According to the Commonwealth Fund in 2018, China has approximately 12,000 public hospitals and 21,000 private hospitals. Similarly, in June 2019, the Indian Ministry of Health and Family Welfare announced the opening of 22 new AIIMS across the country. The significant growth in the number of hospitals and surgical centers is expected to support the growth of the hemostats market, as these are key end users of the hemostats market.

[biomedgrid]

Biomed Grid | The Economic Burden of Bleeds and Transfusions in Selected Surgeries: A Retrospective Multi Center Analysis from the US Perspective

Abstract

Objective: To identify the economic impact of bleeds and transfusions by analyzing the effect of hemostatic agents (active and passive) on adults undergoing Cardio Vascular/Thoracic & Ortho-Ortho Spine surgeries in US hospitals.

Methods: A Retrospective review of intraoperative data from 72 Cardio Vascular/Thoracic, and 39 Ortho-Ortho Spine surgeries performed between August–December 2018, from different US Urban Hospitals was performed to determine the economic impact of bleeding and transfusions associated with the utilization efficiency of active or passive hemostatic agents.

Results: Of the 111 cases analyzed, 157 hemostatic agents were used. Utilization efficiency (a percentage defined as the amount of product used divided by the amount opened) was calculated. Utilization efficiency or products such as Flowable were 84% and Sealants 97%, Products with medium utilization efficiency such as Gelatin Powder were 76% and Oxidized Cellulose 72%, and products with a low utilization efficiency such as Thrombin were 46%, and Gelatin Sponge & Bone Wax 42%. The average estimated blood loss for all surgeries was 455 mL. The total blood product units used included Packed Red Blood Cells (PRBC) 12U, Fresh Frozen Plasma (FFP) and Platelets 10U, and Cryoprecipitate 52U. The economic impact of bleeding and transfusions ranged from $9,824 to $29,296 depending on the surgery and the hemostatic agent used.

Conclusions: Surgical bleeds and transfusions can have substantial financial and medical consequences. Using appropriate hemostatic agents intraoperatively may potentially reduce bleeds requiring transfusion and likely improve patient post-surgical outcomes. The use of active hemostatic agents resulted in a substantial Blood Product Use savings of $19,472 (50%) per patient. The use of active hemostatic agents may result in effective and cost-beneficial outcomes compared with passive hemostatic agents.

Clinical relevance: The use of Active Hemostat Agents may result in better clinical and possibly economic (bleeding and transfusion) outcomes in Cardio Vascular/Thoracic & Ortho-Ortho Spine surgeries.  

Keywords:Hemostatic agents; Active and passive; LUR; Bleeds; Transfusions

Introduction

Bleeding is a complication of surgery that may lead to substantial morbidity and mortality. In different type of surgeries (CV, Vascular, Thoracic, Neuro/Neuro-Spine), severe bleeding occurs in approximately 7% of cases [1] and is associated with an increased risk of post-operative mortality [1]. The burden of bleeding in the United States is costly for patients and for the healthcare system. Patients with uncontrolled intraoperative bleeding can be four times more likely to die from a surgical procedure [4]. These patients receive more blood transfusions, have longer hospital stays and have statistically worse outcomes, including significantly higher morbidity rates. The American Medical Association and the Joint Commission have identified blood transfusions as one of the top five over-utilized therapeutic procedures in the U.S. [4]. Efficient surgeries with limited bleeding may be one potential solution. Notable National Health Organizations have begun to address the issue of how to ensure more efficient utilization of blood transfusions.

Bleeding is an anticipated consequence of virtually all types of surgical procedures. Ideally, every surgical procedure concludes with hemostasis of the surgical field and an optimal patient outcome. The rates of bleeding and bleeding-related complications ranged from 7.5% with reproductive organ procedures to 47.4% with cardiac procedures [4]. Blood transfusions are a common practice in hospitals around the world, where up to 20% of patients who undergone surgery and 35% of patients in intensive care units receive at least one blood transfusion [5,6]. Depending on the bleeding type and the quantity of blood loss, this can lead to substantial morbidity and mortality. The rates of bleeding and bleeding-related complications (hemorrhage, anemia, thrombocytopenia, hematoma, embolic events or venous thrombosis) ranged from 7.5% with reproductive organ procedures to 47.4% with cardiac procedures [7]. Using Blood Products in those high-risk bleeding surgeries can lead to costa ranging from 2,805-$17,279 for reproductive organ and spinal. Patients with bleeding-related complications and/or blood product transfusions experienced longer hospital stay (4.9-18.7 vs. 2.6-9.1 mean days) and spent more time in the ICU (0.2-8.9 vs. 0.04-1.2 mean days) compared to patients without these events [8].

Patients who receive blood transfusions have a substantially higher risk of adverse events, resulting in up to three times longer hospital stays compared to patients who do not receive transfusions. Furthermore, blood transfusions are expensive, given not only the cost of the product, but also the substantial expense of labor associated with blood management. Although necessary in terms of care and its quality, these transfusions involve significant costs. In 2008, four different studies were carried out in the United States which concluded that the costs of blood bags alone varied between $332 and $717 [9,10].

The complexity of surgical procedures, where blood loss can have devastating consequences, creates challenges for a hospital’s resources. If not well managed, intraoperative bleeding can threaten patient near-term and long-term outcomes and expend unnecessary hospital resources. Blood transfusions have become an increasingly frequent practice in U.S. hospitals. In fact, between 1997 and 2011, blood transfusions increased 134 percent. Current estimates show that as many as 40 to 50 percent of blood transfusions may be unnecessary, potentially putting patients’ lives in jeopardy, and could be costing individual hospitals as much as $1 million per year [11,12]. In addition to the supply limitations on blood and the costs associated with transfusions, transfusions may lead to suboptimal patient outcomes. Blood transfusions are frequently associated with longer patient length of stay, increased mortality and morbidity, in addition to increased costs and resource utilization. Reducing the need for blood transfusions by reducing blood loss during surgery, is one solution to eliminate wasteful utilization of resources, likely improve patient post-surgical outcomes and reduce costs to the hospital.

Blood conservation strategies are associated with nearly half the perioperative morbidity of conventional management (39.1% vs. 23.5%, p=0.046), as assessed by a composite of any of 10 major postoperative complications [13]. The implementation of new methods, supported by innovations in medical technology that allow for the continuous measurement of hemoglobin values, would facilitate decision-making regarding transfusions, allowing transfusions where medically necessary and at the right moment, therefore reducing unnecessary transfusions [14].

Methods

A Retrospective analysis intraoperative data for 72 Cardio Vascular/Thoracic procedures and 39 Ortho-Ortho Spine surgeries performed between August and December 2018, from different US Urban Hospitals, whereby, the quantity of bleeding and transfusions associated with the utilization efficiency of active or passive hemostat products was analyzed to determine the economic impact of bleeds and transfusions.

Data Source

Data for this retrospective analysis was obtained from the Live Utilization Review (LUR) US Vitale Edge Data Base Program, a repository of product utilization efficiency, estimated blood loss (EBL), economic and resource use data developed for quality and utilization benchmarking purposes.

The database includes National US representative hospital data based on bed size, geographic region, and teaching hospital status. The database comprises data from 111 cases analyzed (72 Cardio Vascular/Thoracic & 39 Ortho-Ortho Spine surgeries) and 157 hemostatic agents from August-December 2018.

Database Case Selection Criteria

The records of the Cardio Vascular/Thoracic & Ortho-Ortho Spine surgeries included in this retrospective of prospectively collected intraoperative database analysis were of patients that underwent elective or urgent surgeries performed between August- December 2018, from different US Urban Hospitals.

Data Extracted for Analyses

Data regarding surgery types [(Cardio Vascular/Thoracic & Ortho-Ortho Spine), hemostatic agents (active and passive)], energy device, EBL, cell saver used, total blood product units used (packed red blood cells (PRBC), fresh frozen plasma (FFP), platelets and cryoprecipitate) were extracted. Hemostatic agent (active and passive) utilization efficiency was calculated as a percentage defined as the amount of product used divided by the amount opened (Table 1).

Table 1:Hemostatic agent utilization.

Source: Own elaboration with data from US Vital Edge Program, LUR Analyses retrospective analysis.

Statistical Analyses

Hypothesis tests were not made, derived from the conformation on the observational data, full inhibition of bleeding was not assessed with the setup of active/passive hemostatic agents, correlation matrix and linear regression was performed in order to represent the effect of the usage of active and passive hemostatic in the EBL, linear regression showed that the use of active hemostatic agents improve 5 more times the reduction of blood lost (mL).

Methodology

Cost Analyses

Cost analysis was performed by examining the cost (system cost) of using Blood Products (RBC, Platelets, FFP and Cryoprecipitates) from the Society for the Advancement of Blood Management 2018 and Transfusions and Their Costs: Managing Patients Needs and Hospitals Economics, J Basha, R Dewitt, D Cable, G Jones. Transfusions and Their Costs: Managing Patients Needs and Hospitals Economics. The Internet Journal of Emergency and Intensive Care Medicine 2005. The first data entered the matrix were the ratio of units transfused per patient depending on the type of surgeries analyzed, the EBL and the cost of Blood Products used per surgery type and hemostatic product used (active or passive). To create the cost–benefit matrix, the savings obtained from the number of units transfused per surgery type were considered. These savings were classified by different types of surgeries identified by the ratio of units transfused. The total cost of Blood Products used was analysed with the EBL per surgery and hemostatic product (active or passive) used versus those without EBL per surgery and hemostatic product (active or passive used).

Model analyses

This model estimated the results from a retrospective analysis of prospectively collected intraoperative data (72 Cardio Vascular/ Thoracic & 39 Ortho-Ortho Spine surgeries), performed between August-December 2018, from different US Urban Hospitals; the quantity of bleeding and transfusions associated with the utilization efficiency of active or passive hemostat products was analyzed to determine the economic impact of bleeds and transfusions.The cost analysis was performed by examining the cost (system cost) of using Blood Products (RBC, Platelets, FFP and Cryoprecipitates.

Results

Of the 111 cases analyzed, 157 hemostatic agents were used; utilization efficiency (a percentage defined as the amount of product used divided by the amount opened). Utilization efficiency for products such as Flowable 84% and Sealants 97%. Products with medium utilization efficiency included Gelatin Powder76% and Oxidized Cellulose72%. Products with a low utilization efficiency included Thrombin 46%, Gelatin Sponge & Bone Wax 42% (Figure 1). The average estimated blood loss for all surgeries was 455 mL and the total blood product units used included Packed Red Blood Cells (PRBC) 12U, Fresh Frozen Plasma (FFP) and Platelets 10U, and Cryoprecipitate 52U. The average EBL for CV was 631mL, Vascular 479mL, Thoracic 402mL and Orto/Ortho-Spine 358mL, the % of cases requiring any blood transfusion by category was: CV 13.1%, Vascular 13.33% and Thoracic//Ortho/Ortho-Spine 0% and number of cases using cell salvage were: CV 32, Orto/ Ortho-Spine 2 and Vascular/Thoracic 0 (Table 2). The economic impact of bleeding and transfusions ranged from $9,824 to $29,296 depending on the surgery and the hemostatic agent used.

Source: Own elaboration with data from US Vital Edge Program, LUR Analyses retrospective analysis.

Figure 1: Utilization Efficiency by Specialty.

Table 2: Estimated Blood Los and Cell Salvage Used.

Source: Own elaboration with data from US Vital Edge Program, LUR Analyses retrospective analysis.

Discussion

The complexity of surgical procedures in an aging population, where intraoperative blood loss can have devastating consequences, creates challenges for hospital’ resources and, if not well managed, intraoperative bleeding in complex procedures can threaten patient near-term and long-term outcomes and expend unnecessary hospital resources. To address these dynamics and the challenges they present, associations, hospitals, surgeons, and policymakers must consider opportunities to drive new efficiencies in healthcare delivery to optimize patient outcomes. This is particularly important in high-risk surgeries. While there are several ways to create surgical efficiencies, and improve health outcomes, efficiencies that drive lower utilization of blood can indicate adoption of sustainable improvement initiatives across the hospital, resulting in better post-operative outcomes.

In a first step, established and respected institutions like the Society of Thoracic Surgeons, American Society of Anesthesiologists, The Joint Commission, the U.S. Department of Health and Human Services and others have recognized the importance of improving blood management and have proposed clinical guidelines to reduce the need for intraoperative transfusions through preoperative, intra-operative, and post-operative evidence-based recommendations. Beside the above strategies, it is important to choose the proper hemostatic agent (active product) to control/ stop the bleeding and reduce minor or major compactions related to bleeds. It is known that the use of active products can lead to improved intraoperative and postoperative transfusion requirements. Cost calculations reported here are hypothesis generating, do not represent a detailed or formal analysis of cost effectiveness and warrant further confirmation in dedicated economic studies. Nevertheless, based on the estimated $19,472 (50%) per patient cost saving associated with the use of hemostatic agents (active products), it seems that substantial reductions observed for some of the surgical requirements may have directly translated into cost savings (Figure 2).

Figure 2: Economic Impact of Passive and Active Hemostatic Agents of Blood Product Used.

Limitations

All economic models are a simplification of a complex healthcare situation and, hence, bear the limitations associated with a simple representation of the reality. Limitations of the analysis includes it is a retrospective analysis of an observational collected intraoperative data (72 Cardio Vascular/Thoracic & 39 Ortho Ortho Spine surgeries), performed between August-December 2018, from different US Urban Hospitals database design, which is less robust than the conduct of prospective randomized trials and inherently associated with selection biases. In addition, the sample size analyzed Cardio Vascular/Thoracic and Ortho-Spine; if we include other surgical specialties the results may be due to chance. To avoid this, a randomized clinical trial with a larger number of patients and proper measuring on the clinical impact of inhibited blood loss during procedures and the complications derived from this should be carried out.

Conclusion

Surgical bleeds, leakages and transfusions can have substantial financial and medical outcome consequences, the prevention of which would be beneficial for institutions and patients. Reducing the need for blood transfusions by minimizing blood loss during surgery through the efficient use of appropriate hemostat agents could potentially eliminate the wasteful utilization of resources and likely improve patient post-surgical outcomes. The use of hemostatic agents (active products) resulted in a substantial Blood Product Use savings of $19,472 (50%) per patient. The use of hemostatic agents (active products) may result in effective and cost-beneficial as compared with hemostatic agents (passive products) (Table 3).

Table 3: Total Cost Savings of Blood Products Use.

Acknowledgement/Conflict of interest disclosures

Authors (MGR, GFC and MAR) are employees of Baxter Healthcare, which are involved in the manufacture of a product examined in this analysis.

Read More About this Article: https://biomedgrid.com/fulltext/volume2/the-economic-burden-of-bleeds-and-transfusions-in-selected-surgeries.000610.php

For more about: Journals on Biomedical Science :Biomed Grid

[omkeshwari-blog]

Global Gelfoam Market Growth 2019-2024

In order to prevent hemorrhage during surgical procedures, a wide range of hemostatic agents have been developed. And in our report, we study the hemostasis and tissue sealing agents made of gelatin matrix thrombin.

North America is the largest consumption place, with a consumption market share nearly 42% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 31%.

Request Sample Report @ https://www.acquiremarketresearch.com/sample-request/779

According to this study, over the next five years the Gelfoam market will register a 5.6% CAGR in terms of revenue, the global market size will reach US$ 1020 million by 2024, from US$ 740 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Gelfoam business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Gelfoam market by product type, application, key manufacturers and key regions and countries.

This study considers the Gelfoam value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.

Sponge

Powder

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.

Minimally Invasive Surgery

General Surgery

Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

APAC

Europe

Middle East & Africa

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

Johnson & Johnson

Gelita

Pfizer 

Baxter

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Gelfoam consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.

To understand the structure of Gelfoam market by identifying its various sub segments.

Focuses on the key global Gelfoam manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Gelfoam with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Gelfoam submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

More info and TOC @ https://www.acquiremarketresearch.com/industry-reports/global-gelfoam-market-growth-2019-2024/779/

Table of Content:

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

 About Acquire Market Research:

Acquire Market Research is a shrine of world-class research reports from around the world and we offer you only the best in the Industry when it comes to research. At Acquire, every data need will be catered to and met with a powerful world of choices. "We understand the integral role data plays in the growth of Business empires."

Contact us: 555 Madison Avenue, 5th Floor, Manhattan, New York, 10022 USA Phone No.: +1 (800) 663-5579 Email ID: sales@acquiremarketresearch.com

[healthcaremarkettrend]

Hemostats Market | Increasing Number of Surgeries

Growth in this market is driven by the increasing number of surgical procedures, growing number of regulatory approvals, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries. In addition, the emerging markets and growth in the number of hospitals and surgical centers are expected to offer further growth opportunities for players operating in the hemostats market. On the other hand, high cost of hemostats and dearth of skilled professionals are expected to hinder the growth of this market. How much is the Hemostats Market worth? The global hemostats market is expected to reach USD 3.03 billion by 2023 from USD 2.27 billion in 2018, at a CAGR of 6.0% during the forecast period. Growth in the market is majorly driven by the growing geriatric population and increasing number of surgeries in the region. North America is expected to register the highest growth rate during the forecast period mainly due the growing geriatric population and increasing number of surgeries in the region. Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9571619 The thrombin-based hemostats segment is expected to account for the largest share of the market in 2018. Based on product, the hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Of all these product segments, the thrombin-based hemostats segment is expected to account for the largest share of the global hemostats market in 2018. The large share of this market segment can primarily be attributed to the wide range of advantages associated with the use of thrombin-based hemostats. In 2018, the orthopedic surgery segment is expected to dominate the hemostats market On the basis of application, the hemostats market is segmented neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries. The orthopedic surgery segment is expected to account for the largest share of the hemostats market in 2018. The growing geriatric population, increasing incidence of sports injuries, and the growing prevalence of lifestyle disorders (such as arthritis, osteoporosis, and obesity) are some of the major factors responsible for the growth in the number of orthopedic surgeries performed globally. The growing number of orthopedic surgeries is in turn expected to support the growth of dependent markets, such as the hemostats market for orthopedic applications. Based on formulation, the hemostats market is further segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. Based on formulation, the hemostats market is further segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2018, the matrix & gel hemostats segment is expected to account for the largest share of the hemostats market. The large share of this market segment can primarily be attributed to the advantages associated with the use of these formulations, such as lightweight and ease of use. Sponge hemostats, on the other hand, are expected to witness the highest growth in the market during the forecast period. Market growth can largely be attributed to the growing acceptance of these formulations by end users. Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=9571619 This report covers the market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North Americais expected to register the highest growth rate during the forecast period mainly due the growing geriatric population and increasing number of surgeries in the region. Geographically, the medical tapes and medical bandages market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2018, North America is expected to account for the largest share of the global hemostats market. The hemostats market in North America is well-established, with the US being a major market in this region. Growth in the North American market is majorly driven by the growing geriatric population and increasing number of surgeries in the region. Leading Companies CR Bard, Inc. (US), B. Braun Melsungen AG (Germany), Baxter International, Inc. (US), Integra LifeSciences (US), Marine Polymer Technologies, Inc. (US), Teleflex (US), Ethicon, Inc. (US), Pfizer, Inc. (US), Z-Medica LLC (US), and Gelita Medical GmbH (Germany). Inquiry before Buying @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=9571619

[marketresearchstrategy]

Hemostat  Market Share, Industry Growth, Trend, Drivers, Challenges, Key Companies by 2026

The global hemostat market is a fast-growing sector and is widely driven by the increasing number of surgeries acquainted with chronic disorders and the rise in the number of sports accidents among athletes and gymnasts.

the hemostats market was valued at USD 2.11 billion in 2018 and is expected to reach USD 3.46 billion by the year 2026, at a CAGR of 6.2%. It is a surgical instrument that is used to control the flow of blood during surgical procedures. These surgical hemostats are used in the initial steps of surgery when an incision is performed. It can be used in various forms like sealants, topical hemostats, and mechanical instruments, which are meant for surgical use only. The major goal of a hemostat is the adhesion of wounds, to cease blood flow, and ensure rapid healing of the wound. The hemostat market is widely driven by the free fall in lifestyle due to which lifestyle-oriented diseases occur in many people. Various diseases, especially cardiovascular and orthopedic diseases, are treated through surgical procedures, which is extensively driving the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2516

The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.

Key Manufacturers in the Global Hemostat  Market:

Johnson and Johnson, Baxter International, Pfizer, Integra Life Sciences, Z-Medica LLC, Abbott Laboratories, B. Braun Melsungen AG, CR Bard, Gelita Medical GmbH and Hemostasis LLC.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2516

The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of Europe)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Product Outlook (Revenue in Million USD; 2016–2026)

Thrombin-based hemostats

Gelatin-based hemostats

Collagen-based hemostats

Combination hemostats

Oxidized regenerated cellulose-based hemostats

Application Outlook (Revenue in Million USD; 2016–2026)

General surgery

Orthopedic surgery

Cardiovascular surgery

Reconstructive surgery

Gynecological surgery

Neurological surgery

Other surgeries

Formulation Outlook (Revenue in Million USD; 2016–2026)

Sheet & pad hemostat

Sponge hemostats

Matrix & gel hemostats

Powder hemostat

End Use Outlook (Revenue in Million USD; 2016–2026)

Hospitals

Clinics

Ambulatory centers

Community healthcare

Others

To know more about the report @ https://www.reportsanddata.com/report-detail/hemostat-market

Key Questions Addressed in the Report:

What is the market size the global Hemostat  market is expected to reach over the forecast period? What is the expected CAGR?

What are the key segments of the market?

What are the key products and applications of the Hemostat  market?

What factors are expected to drive and restrain market growth over the forecast period?

What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2516

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.

Browse more Details:

Neuroscience Antibodies and Assays Market:      https://www.biospace.com/article/neuroscience-antibodies-and-assays-market-size-to-reach-usd-7-06-billion-in-2028-says-reports-and-data-/

Cochlear Implant Market:             https://www.biospace.com/article/cochlear-implant-ci-market-size-to-reach-usd-4-21-billion-in-2028-noted-reports-and-data-/

Creatinine Measurement Market:            https://www.biospace.com/article/creatinine-measurement-market-size-to-value-at-usd-841-01-million-in-2028/

Lung In Vitro Model Market:       https://www.biospace.com/article/lung-in-vitro-market-size-to-reach-usd-976-9-million-in-2028-says-reports-and-data/

C-Reactive Protein Testing Market:          https://www.biospace.com/article/c-reactive-protein-testing-market-size-to-reach-usd-1-93-billion-in-2028-says-reports-and-data-/

[data-bridge-market-research]

Hemostats Market Key Players: Ethicon US LLC, Baxter, Teleflex Incorporated, B. Braun Melsungen AG

Global hemostats market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hemostats market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Global Hemostats Market is expected to rise from its initial estimated value of USD 3.06 billion in 2018 to an estimated value of USD 5.02 billion by 2026, registering a CAGR of 6.4% in the forecast period of 2019-2026. This rise in market value can be attributed to the rising number of surgical procedures.

Download PDF Sample Copy of Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-hemostats-market

Key Market Competitors: Global Hemostats Market 

·         Ethicon US LLC (US),

·         Baxter (US),

·         Teleflex Incorporated (US),

·         B. Braun Melsungen AG (Germany),

·         3-D Matrix Medical Technology (Japan),

·         RESORBA Medical GmbH,

·         Anika Therapeutics, Inc. (US),

·         Arch Therapeutics, Inc. (US),

·         Biom’up SAS,

·         CryoLife, Inc. (US),

·         Gamma Therapeutics, Inc. (US),

·         Hemostasis, LLC. (USA),

·         MedTrade Products Limited (UK),

·         Integra LifeSciences (US),

·         Medline Industries, Inc (US),

·         HEMOTEC MEDICAL GMBH (Germany),

·         Stryker (US),

·         CSL (US),

·         Mallinckrodt company (UK),

·         Equimedica (Europe),

·         Others.

Key Developments in the Market:

·         In April 2019, Biom’up announced that the U.S. Food and Drug Administration (FDA) approved the IDE (Investigational Device Exemption) application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures.

·         In January 2019, Biom’up Company, specializing in surgical hemostasis announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its HEMOBLAST Bellows Laparoscopic Applicator for all minimally-invasive procedures.

Market Definition: Global Hemostats Market 

The hemostat can be defined as a surgical tool which is used to control blood loss or halt bleeding during major surgical. Basically it is used in early phases of surgery for an initial incision that closes blood vessels until ligation. It contain group of instruments which include needle holders, pivot, various clamps and various clamps.

According to the American Joint Replacement Surgery 2016, around 427,181 total surgical procedures were reported for joint replacement surgery in the U.S. However, the cluttering of surgical field due to multiple clamp attachment causing inconvenience to the surgeons and thus, leading to surgical errors is expected to hinder the market growth.

Market Drivers

·         Increasing healthcare expenditure and infrastructure, this significant act as driver to the market.

·         Increasing number of technological advancement, this significant act as driver to the market.

Market Restraints

·         Highly consolidated market, this act as restraints to the market.

Order a Copy of Global Hemostats Market Report @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hemostats-market

Segmentation: Global Hemostats Market 

By Product Type

·         Thrombin Based

·         Combination

·         Oxidized Regenerated Cellulose Based

·         Gelatin Based

·         Collagen Based Hemostat

By Indication

·         Wound Closure

·         Surger

By Formulation

·         Matrix & Gel Hemostats

·         Sheet & Pad Hemostats

·         Sponge Hemostats

·         Powder Hemostats

By Application

·         Orthopedic Surgery

·         General Surgery

·         Neurological Surgery

·         Cardiovascular Surgery

·         Reconstructive Surgery

·         Gynecological Surgery

By End User

·         Hospitals

·         Clinics

·         Ambulatory Centers

·         Community Healthcare

·         Others

By Geography

·         North America

·         South America

·         Europe

·         Asia-Pacific

·         Middle East & Africa

Reasons to Purchase this Report

·         Current and future of global hemostats market outlook in the developed and emerging markets

·         The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

·         Regions/Countries that are expected to witness the fastest growth rates during the forecast period

·         The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

·         All segmentation provided above in this report is represented at country level

·         All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Table of Contents:

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY

1.2. MARKET DEFINITION

1.3. OVERVIEW OF GLOBAL HEMOSTATS MARKET

1.4. CURRENCY AND PRICING

1.5. LIMITATION

1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED

2.2. GEOGRAPHIC SCOPE

2.3. YEARS CONSIDERED FOR THE STUDY

2.4. CURRENCY AND PRICING

2.5. RESEARCH METHODOLOGY

2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7. SECONDARY SOURCE

2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.2. RESTRAINTS

3.3. OPPORTUNITIES

3.4. CHALLENGES

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW

5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW

6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. GLOBAL HEMOSTATS MARKET, BY TYPE

9. GLOBAL HEMOSTATS MARKET,BY APPLICATION

10. GLOBAL HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

11. GLOBAL HEMOSTATS MARKET, BY END USER

12. GLOBAL HEMOSTATS MARKET, BY GEOGRAPHY

13. GLOBAL HEMOSTATS MARKET, COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: GLOBAL

13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA

13.3. COMPANY SHARE ANALYSIS: EUROPE

13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC)

14.2. PFIZER

14.3. C.R BARD

14.4. BAXTER

14.5. VASCULAR SOLUTIONS, INC (ACQUIRED BY TELEFLEX INCORPORATED)

14.6. B.BRAUN MELSUNGEN AG

14.7. 3-D MATRIX LTD

14.8. RESORBA MEDICAL GMBH

14.9. ANIKA THERAPEUTICS, INC.

14.10. BIOM’UP

14.11. CRYOLIFE, INC.

14.12. EQUIMEDICAL

14.13. HEMOSTASIS, LLC

14.14. MEDTRADE PRODUCTS LIMITED

14.15. STRYKER

14.16. ARCH THERAPEUTICS, INC.

14.17. INTEGRA LIFESCIENCES CORPORATION

14.18. ALTAYLAR MEDICAL

14.19. BIOCER ENTWICKLUNGS-GMBH

14.20. SMI (STARCH MEDICAL)

Get Detailed TOC @ https://databridgemarketresearch.com/toc/?dbmr=global-hemostats-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:                                                

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 

Email: Corporatesales@databridgemarketresearch.com